Literature DB >> 9620553

Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation.

M Falasca1, C Iurisci, A Carvelli, A Sacchetti, D Corda.   

Abstract

Lysophosphatidylinositol (LysoPtdIns) is formed by a constitutively-active phosphoinositide-specific phospholipase A2 in Ras-transformed cells and can stimulate cell proliferation. To evaluate whether LysoPtdIns could function as an autocrine modulator of cell growth, we examined whether LysoPtdIns can be released in the medium of Ras-transformed FRT-Fibro fibroblasts and thyroid cells. Here, we report that LysoPtdIns accumulates in the extracellular space of these lines and reaches levels up to tenfold higher than in the case of normal cells. Moreover, the ionophore A23187 increased the levels of the lysolipid in the extracellular medium. Extracellular LysoPtdIns was rapidly hydrolyzed to inositol 1:2-cyclic phosphate. LysoPtdIns induced thymidine incorporation in FRT-Fibro Ha-Ras fibroblasts, whereas inositol cyclic 1:2-cyclic phosphate did not affect cell growth per se, nor did it interfere with the LysoPtdIns mitogenic activity. We hypothesize that in Ras-transformed fibroblasts the formation and release of LysoPtdIns may function as an autocrine mechanism that participates in the Ras-dependent stimulation of cell growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620553     DOI: 10.1038/sj.onc.1201758

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

Review 1.  The glycerophosphoinositols: cellular metabolism and biological functions.

Authors:  Daniela Corda; Pasquale Zizza; Alessia Varone; Beatrice Maria Filippi; Stefania Mariggiò
Journal:  Cell Mol Life Sci       Date:  2009-08-09       Impact factor: 9.261

2.  GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Authors:  R Ferro; A Adamska; R Lattanzio; I Mavrommati; C E Edling; S A Arifin; C A Fyffe; G Sala; L Sacchetto; G Chiorino; V De Laurenzi; M Piantelli; O J Sansom; T Maffucci; M Falasca
Journal:  Oncogene       Date:  2018-07-30       Impact factor: 9.867

Review 3.  Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.

Authors:  Christopher M Henstridge; Nariman A B Balenga; Julia Kargl; Clara Andradas; Andrew J Brown; Andrew Irving; Cristina Sanchez; Maria Waldhoer
Journal:  Mol Endocrinol       Date:  2011-09-29

4.  GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils.

Authors:  Nariman A B Balenga; Elma Aflaki; Julia Kargl; Wolfgang Platzer; Ralf Schröder; Stefanie Blättermann; Evi Kostenis; Andrew J Brown; Akos Heinemann; Maria Waldhoer
Journal:  Cell Res       Date:  2011-04-05       Impact factor: 25.617

5.  The natural phosphoinositide derivative glycerophosphoinositol inhibits the lipopolysaccharide-induced inflammatory and thrombotic responses.

Authors:  Mariangela Vessichelli; Stefania Mariggiò; Alessia Varone; Pasquale Zizza; Angelomaria Di Santo; Concetta Amore; Giuseppe Dell'Elba; Adele Cutignano; Angelo Fontana; Carmela Cacciapuoti; Gaetano Di Costanzo; Mariastella Zannini; Tiziana de Cristofaro; Virgilio Evangelista; Daniela Corda
Journal:  J Biol Chem       Date:  2017-06-09       Impact factor: 5.157

6.  The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.

Authors:  Y M AlSuleimani; C R Hiley
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

7.  Reorganization of actin cytoskeleton by the phosphoinositide metabolite glycerophosphoinositol 4-phosphate.

Authors:  Raffaella Mancini; Enza Piccolo; Stefania Mariggio'; Beatrice Maria Filippi; Cristiano Iurisci; Paolo Pertile; Christopher P Berrie; Daniela Corda
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

Review 8.  A narrative review of urinary phospholipids: from biochemical aspect towards clinical application.

Authors:  Xin Li; Kenji Nakayama; Takayuki Goto; Shusuke Akamatsu; Takashi Kobayashi; Koji Shimizu; Osamu Ogawa; Takahiro Inoue
Journal:  Transl Androl Urol       Date:  2021-04

Review 9.  The therapeutic potential of orphan GPCRs, GPR35 and GPR55.

Authors:  Derek M Shore; Patricia H Reggio
Journal:  Front Pharmacol       Date:  2015-04-15       Impact factor: 5.810

10.  Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management.

Authors:  Dinorah Leyva-Illades; Sharon Demorrow
Journal:  Cancer Manag Res       Date:  2013-07-01       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.